Latest Transposon Therapeutics News & Updates

See the latest news and media coverage for Transposon Therapeutics. We track all announcements, press releases, and industry mentions in real time, all in one place.

Transposon Therapeutics

Developer of reverse transcriptase inhibitors for neurodegenerative diseases

transposonrx.com

Headquarters: San Diego, United States
Founded year: 2020
Company type: Private company
Number of employees: 10–50

Last updated Today

Latest news about Transposon Therapeutics

In short: Transposon Therapeutics advanced its TPN-101 pipeline for neurodegenerative diseases and expanded its oncology portfolio through acquisition.

Company announcements

March 4 Transposon Therapeutics

Transposon Therapeutics receives ARPA-H award for TPN-101

The up to $22M funding supports studying TPN-101 to extend healthspan under the PROSPR program. It targets LINE-1 inhibition to slow aging-related diseases.

9 July 2025 Transposon Therapeutics

Transposon receives ADDF investment for TPN-101 Alzheimer’s trial

Plans Phase 2 trial in Q4 2025, building on positive PSP and ALS results. Advances in HEALEY ALS trial.

28 May 2025 Transposon Therapeutics

Transposon Therapeutics announces TPN-101 inclusion

TPN-101 joins Phase 2/3 HEALEY ALS Platform Trial after promising Phase 2 results in C9orf72-related ALS.

3 December 2024 Transposon Therapeutics

Transposon Therapeutics presents Phase 2 results of TPN-101

Treatment shows clinical benefits on ALSFRS-R, SVC, and lowers NfL, IL-6 biomarkers at ALS/MND Symposium.

Media coverage

March 4 EurekAlert!

URochester researchers awarded up to $22M to study a hidden driver of aging

What if people could stay healthier, stronger, and mentally sharper as they grow older—not by treating diseases one by one but by slowing a biological...

9 July 2025 MENAFN

Transposon Receives Investment From The Alzheimer's Drug Discovery Foundation To Support Advancement Of TPN-101 For The Treatment Of Alzheimer's Disease

Building on the positive results of Phase 2 clinical trials in PSP and ALS, Transposon plans to initiate a Phase 2 clinical trial of TPN-101...

28 May 2025 WDHN

Transposon Announces TPN-101 Selected for Inclusion in the Phase 2/3 HEALEY ALS Platform Trial, Building on the Success of Phase 2 Study in C9orf72-related ALS

News provided by Transposon Therapeutics May 28, 2025, 8:00 AM ET In the Phase 2 Study of TPN-101 in patients with C9orf72-related ALS, TPN-101 showed...

13 January 2025 WGNO

Transposon Therapeutics Strengthens and Expands Development Pipeline with the Acquisition of a Portfolio of Novel Nucleoside Analogs for Oncology

Builds upon leadership position in developing best-in-class, late-stage nucleoside reverse transcriptase inhibitors for neurodegenerative and autoimmune diseases SAN DIEGO, Nov. 21, 2024 /PRNewswire/ -- Transposon...

Never miss news about Transposon Therapeutics

Track Transposon Therapeutics and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Transposon Therapeutics competitors & trending companies

Browse news for competitors to Transposon Therapeutics and other trending companies.